CELLECTIS News

JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target

JMP Securities analyst Silvan Tuerkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $6 price target.

BenzingaMay 31 11:28 ET

Cellectis Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 124.72% JMP Securities $6 → $6 Reiterates Market Outperform → Market Outperform 11/01/2023 124.

BenzingaMay 31 11:26 ET

Positive Outlook for Cellectis SA With Strategic AstraZeneca Partnership and Promising Clinical Developments

TipRanksMay 31 00:25 ET

Earnings Call Summary | Cellectis(CLLS.US) Q1 2024 Earnings Conference

The following is a summary of the Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript:Financial Performance:Cellectis reported a net income of $5.6 million for Q1 2024, reflecting a significant imp

moomoo AIMay 30 23:41 ET · Conference Call

Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)

TipRanksMay 30 22:10 ET

Earnings Call: Cellectis Reports an Additional Investment of $140 Million From AstraZeneca

InvestingMay 30 15:30 ET

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

Earnings Call TranscriptsMay 30 14:06 ET

Press Release: Cellectis' Annual Shareholders General Meeting to Be Held on June 28, 2024

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stag

Dow JonesMay 29 16:30 ET

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)

TipRanksMay 29 05:51 ET

Cellectis Fortifies Cash Reserves, Advances Trials

TipRanksMay 28 18:03 ET

Cellectis Q1 Adj $(0.14) Beats $(0.33) Estimate, Sales $6.50M Beat $3.70M Estimate

Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.33) by 57.58 percent. This is a 74.55 percent increase over losses of $(0.55) pe

BenzingaMay 28 16:33 ET

Earnings Flash (CLLS) CELLECTIS Posts Q1 Revenue $6.5M

04:32 PM EDT, 05/28/2024 (MT Newswires) -- Earnings Flash (CLLS) CELLECTIS Posts Q1 Revenue $6.5M

MT NewswiresMay 28 16:32 ET

Press Release: Cellectis Reports Financial Results for First Quarter 2024

Cellectis Reports Financial Results for First Quarter 2024 -- Cellectis announced completion of the additional equity investment of $140M by AstraZeneca -- Cash position of $143 million as of Marc

Dow JonesMay 28 16:30 ET

Cellectis to Unveil Q1 2024 Financials

TipRanksMay 28 08:39 ET

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies,

GlobeNewswireMay 27 16:30 ET

Cellectis SA Schedules Shareholder Meeting and Proposes Capital Changes

TipRanksMay 24 16:57 ET

Monthly Information on Share Capital and Company Voting Rights

Yahoo FinanceMay 16 16:30 ET

Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)

TipRanksMay 8 00:50 ET

AstraZeneca Concludes Equity Investment in Cellectis

Yahoo FinanceMay 7 04:31 ET

Express News | Cellectis Shares Are Trading Higher After the Company Announced the Completion of the Additional Equity Investment by AstraZeneca

BenzingaMay 6 14:34 ET